Journal: Free radical research
Article Title: OXIDIZED LDL CHOLESTEROL, STATIN USE AND MORBIDITY-MORTALITY IN PATIENTS RECEIVING MAINTENANCE HEMODIALYSIS.
PMID/MRN: 27667446
Publication Date: 2016-Sep-25
Abstract:
Statin treatment reduces the risk of cardiovascular mortality in the general population, but it has little or no benefit in hemodialyzed patients (HD). This may reflect different underlying pathophysiology of CVD in patients treated with HD, maybe involving the oxidative stress. Our aim was to assess the association of oxidized LDL (oxLDL), determinated by Mercodia oxLDL ELISA Kit, with major adverse cardiac events (MACE) and all-cause mortality in HD patients based on the AURORA trial (rosuvastatin vs placebo), and patients not on HD from the LURIC study. We also assessed whether its decrease due to statin use improves these outcomes using Cox proportional hazard models. Baseline oxLDL level was 34.2 ± 13.8 U/L in AURORA, and did not differ between treatment groups, and 74.6±28.1 U/L in LURIC. Lower baseline oxLDL levels were associated with higher HRs for outcomes, but not anymore after adjusting for apolipoprotein B level in AURORA and was not related to mortality in LURIC. OxLDL levels decreased by 30.9% between baseline and 3 months in the statin-treated group, and increased by 10.5% between 3 and 12 months. Nevertheless, oxLDL reduction was not significantly associated with adjusted HRs for MACE and for all-cause mortality These results showed no association between oxLDL and MACE after adjustment on apolipoprotein B probably related to the technical limitation of the Mercodia method. Our results also showed no benefit for oxLDL reduction by rosuvastatin on outcomes. Future clinical trials are needed to define the relative CVD risks and benefits of other modalities of oxidative stress modification in this population.